Form 8-K

8-K — STANDARD BIOTOOLS INC.

Accession: 0001193125-26-335106

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001162194

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — lab-20260805.htm (Primary)

EX-99.1 (lab-ex99_1.htm)

GRAPHIC (img96762296_0.gif)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: lab-20260805.htm · Sequence: 1

8-K

0001162194 false00011621942026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 5, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of

incorporation or organization)

001-34180

(Commission File Number)

77-0513190

(I.R.S. Employer Identification Number)

50 Milk Street, 10th Floor

Boston, Massachusetts 02109

(Address of principal executive offices and zip code)

(650) 266-6000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, $0.001 par value per share

LAB

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On August 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2026. The press release is attached hereto as Exhibit 99.1.

The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure

The information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press release issued by Standard BioTools Inc., dated August 5, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

August 5, 2026

STANDARD BIOTOOLS INC.

By:

/s/ Alex Kim

Name:

Alex Kim

Title:

Chief Financial Officer

EX-99.1

Filename: lab-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Standard BioTools Reports Second Quarter 2026 Financial Results

BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.

Recent Highlights:

•

Second quarter 2026 revenue of $20.1 million

•

1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-year

•

Merger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026

“We remain on track to close our merger with Treeline Biosciences in 2026, with our previously filed registration statement on Form S-4, our agreement to divest our Mass Cytometry business, and Illumina’s early buyout of contingent payments for $30 million from its acquisition of SomaLogic,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We continue to believe this merger is the best path forward to maximize shareholder value, providing exposure to a catalyst-rich, well-capitalized pipeline of potential new therapeutics with significant near and long term value creation opportunities, and we look forward to updating stockholders as we progress toward the vote and closing.”

Dr. Egholm continued, “While the transaction process continues, our team remains focused on serving our customers. Our continued cost discipline drove an 84% year-over-year improvement in adjusted EBITDA for the second quarter.”

Financial Results Table: Continuing Operations

Three Months Ended June 30,

Six Months Ended June 30,

(Unaudited, in millions, except percentages)

2026

2025

2026

2025

Revenue

20.1

21.8

41.3

42.0

Gross margin

52.4

48.8

53.0

51.6

Non-GAAP gross margin

56.3

54.1

57.0

55.6

Operating expenses

35.9

36.3

59.7

74.3

Non-GAAP operating expenses

13.8

27.9

29.1

53.5

Operating loss

(25.4

)

(25.7

)

(37.9

)

(52.7

)

Net loss from continuing operations

(21.5

)

(17.7

)

(36.2

)

(41.0

)

Adjusted EBITDA

(2.5

)

(16.1

)

(5.6

)

(30.2

)

Cash, cash equivalents, restricted cash, short-term and long-term investments

541.1

227.9

541.1

227.9

Second Quarter 2026 Financial Results:

•

Revenue was $20.1 million in the second quarter of 2026, down 7.6% year-over-year.

•

Consumables revenue was $9.4 million in the second quarter of 2026, down 10% year-over-year, compared against particularly strong prior year results and continued US Academia spend uncertainty.

•

Instruments revenue was $5.1 million in the second quarter of 2026, down 2% year-over-year. Instrument revenue in the quarter remained impacted by capital-constrained end-markets.

•

Services revenue, which is predominantly Field Services, was $5.6 million in the second quarter of 2026, down 8% year-over-year.

•

Gross margins in the second quarter of 2026 were approximately 52.4%, versus 48.8% in the second quarter of 2025; and non-GAAP gross margins in the second quarter of 2026 were approximately 56.3%, versus 54.1% in the second quarter of 2025. Gross margins and non-GAAP gross margins were driven by productivity improvements and reduced warranty expense.

•

Operating expenses in the second quarter of 2026 were $35.9 million, a decrease of $0.4 million, or down 1%, compared to the second quarter of 2025. Operating expenses included $14.7 million in transaction costs and $2.8 million in restructuring and related charges. Non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $13.8 million in the second quarter of 2026, a decrease of $14.1 million, or down 50%, compared to the second quarter of 2025. The decrease in operating expenses was largely due to previously announced restructuring actions.

•

Net loss for the second quarter of 2026 was $21.5 million from continuing operations, compared to a net loss of $17.7 million in the second quarter of 2025, representing a change of $3.8 million or 21%. This was impacted by one-time transaction costs. Adjusted EBITDA for the second quarter of 2026 was a loss of $2.5 million, versus an adjusted EBITDA loss of $16.1 million in the second quarter of 2025, an improvement of $13.6 million, or 84%.

Full Year 2026 Revenue Outlook

Standard BioTools is withdrawing its full year 2026 revenue outlook given the pending merger with Treeline Biosciences.

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP financial measures are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance; the anticipated timing and completion of the proposed merger with Treeline Biosciences, including with respect to the timing of the closing and the anticipated benefits and value creation opportunities of the proposed merger; the proposed sale of the Company’s Mass Cytometry business and the anticipated timing of the closing of that transaction; operational and strategic plans; deployment of capital; and market and growth opportunity and potential. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the proposed merger with Treeline Biosciences may not be completed on the anticipated timeline or at all, including risks related to obtaining stockholder approval and satisfying other closing conditions; risks related to the proposed sale of the Mass Cytometry business, including risks that the transaction may not

close on the anticipated timeline or at all; the potential that the expected benefits and opportunities of the proposed merger may not be realized or may take longer to realize than expected; possible integration, restructuring and transition-related disruption resulting from the proposed transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; management distraction and reduced operating performance during the pendency of the proposed transactions; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; existing and potential future NIH funding pressures; the effect from existing and potential future U.S. export controls and tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K, for the year ended December 31, 2025, filed with the SEC on March 16, 2026, the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2026, to be filed with the SEC, the Company’s registration statement on Form S-4, filed with the SEC on July 20, 2026 in connection with the proposed merger with Treeline Biosciences, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.

Patent and License Information: standardbio.com/legal/notices.

Investor Contact:

ir@standardbio.com

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenue:

Product revenue

14,515

15,673

29,969

30,454

Services and other revenue

5,589

6,089

11,281

11,530

Total revenue

20,104

21,762

41,250

41,984

Cost of revenue:

Cost of product revenue

6,797

7,608

14,503

14,039

Cost of services and other revenue

2,772

3,526

4,904

6,268

Total cost of revenue

9,569

11,134

19,407

20,307

Gross profit

10,535

10,628

21,843

21,677

Operating expenses:

Research and development

1,976

6,222

4,093

11,662

Selling, general and administrative

16,388

28,105

34,995

57,929

Restructuring and related charges

2,812

1,727

5,892

3,279

Transaction and integration expenses

14,747

271

14,747

1,474

Total operating expenses

35,923

36,325

59,727

74,344

Loss from operations

(25,388

)

(25,697

)

(37,884

)

(52,667

)

Interest income, net

4,611

2,452

8,122

5,366

Other (expense) income, net

(658

)

4,963

(6,288

)

5,530

Loss before income taxes

(21,435

)

(18,282

)

(36,050

)

(41,771

)

Income tax (expense) benefit

(90

)

609

(101

)

728

Net loss from continuing operations

(21,525

)

(17,673

)

(36,151

)

(41,043

)

Discontinued operations:

(Loss) income from discontinued operations, net of tax

(5,233

)

(15,786

)

136,461

(18,449

)

Net (loss) income

(26,758

)

(33,459

)

100,310

(59,492

)

Net loss per share from continuing operations

(0.06

)

(0.05

)

(0.09

)

(0.11

)

Net income (loss) per share from discontinued operations

(0.01

)

(0.04

)

0.35

(0.05

)

Net income (loss) per share

(0.07

)

(0.09

)

0.26

(0.16

)

Shares used in computing net loss per share attributable to common stockholders, basic and diluted

390,881

380,498

389,549

379,369

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

June 30,

December 31,

2026

2025

ASSETS

Current assets:

Cash and cash equivalents

270,026

120,863

Short-term investments

206,693

66,712

Accounts receivable, net

15,747

13,431

Inventory

17,103

19,981

Prepaid expenses and other current assets

7,298

4,871

Current assets held for sale

—

228,406

Total current assets

516,867

454,264

Property and equipment, net

15,300

19,275

Operating lease right-of-use asset, net

24,246

26,732

Other non-current assets

3,261

3,154

Long-term investments

67,280

25,701

Deferred tax asset, non-current

264

38,628

Total assets

627,218

567,754

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

9,554

5,407

Accrued liabilities

29,608

29,783

Operating lease liabilities, current

5,621

5,490

Deferred revenue, current

9,144

38,949

Deferred grant income, current

2,875

3,046

Current liabilities held for sale

—

25,633

Total current liabilities

56,802

108,308

Convertible notes, non-current

299

Deferred tax liability

823

810

Operating lease liabilities, non-current

22,167

25,038

Deferred revenue, non-current

3,146

3,503

Deferred grant income, non-current

2,896

4,290

Other non-current liabilities

1,114

1,215

Total liabilities

87,247

143,463

Total stockholders’ equity

539,971

424,291

Total liabilities and stockholders’ equity

627,218

567,754

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Continuing and Discontinued Operations

(In thousands)

(Unaudited)

Six Months Ended June 30,

2026

2025

Operating activities

Net income (loss)

100,310

(59,492

)

Gain on sale of business

(172,289

)

—

Indemnification-related loss

4,212

—

Stock-based compensation expense

12,874

15,396

Amortization of acquired intangible assets

—

1,715

Depreciation and amortization

2,681

6,450

Accretion of discount on investments, net

(1,839

)

(1,571

)

Realized gain on equity investments

(1,187

)

—

Unrealized loss on equity investments

2,542

—

Non-cash lease expense

2,600

2,865

Provision for excess and obsolete inventory

1,770

1,360

Change in fair value of warrants

—

(232

)

Change in fair value of contingent consideration

—

(3,400

)

Other non-cash items

477

Changes in assets and liabilities, net

(8,628

)

(14,519

)

Net cash used in operating activities

(56,908

)

(50,951

)

Investing activities

Cash received for sale of business, net

388,214

—

Purchases of short-term investments

(127,208

)

(50,929

)

Purchases of long-term investments

(109,845

)

—

Purchases of marketable equity securities

(839

)

—

Proceeds from sales of equity investments

3,090

—

Proceeds from sales and maturities of investments

53,000

100,000

Purchases of property and equipment

(914

)

(6,941

)

Net cash provided by investing activities

205,498

42,130

Financing activities

Proceeds from ESPP stock issuance

120

308

Payments for taxes related to net share settlement of equity awards and other

(376

)

(246

)

Proceeds from exercise of stock options

—

Net cash provided by (used in) financing activities

(178

)

Effect of foreign exchange rate fluctuations on cash and cash equivalents

409

1,145

Net (decrease) increase in cash, cash equivalents and restricted cash

148,821

(7,614

)

Cash, cash equivalents and restricted cash at beginning of period

123,296

168,818

Cash, cash equivalents and restricted cash at end of period

272,117

161,204

Cash, cash equivalents, and restricted cash consists of:

Cash and cash equivalents

270,026

158,617

Restricted cash

2,091

2,587

Total cash, cash equivalents and restricted cash

272,117

161,204

STANDARD BIOTOOLS INC.

REVENUE

Continuing Operations

(In thousands)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Product revenue:

Instruments

5,130

5,215

9,600

11,861

Consumables

9,385

10,458

20,369

18,593

Total product revenue

14,515

15,673

29,969

30,454

Services and other revenue

5,589

6,089

11,281

11,530

Total revenue

20,104

21,762

41,250

41,984

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

Continuing Operations

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Gross profit

10,535

10,628

21,843

21,677

Depreciation and amortization

338

554

684

817

Stock-based compensation expense

453

402

994

644

Loss on disposal of property and equipment

—

187

—

187

Non-GAAP gross profit

11,326

11,771

23,521

23,325

Gross margin percentage

52.4

48.8

53.0

51.6

Depreciation and amortization

1.6

2.6

1.6

2.0

Stock-based compensation expense

2.3

1.8

2.4

1.6

Loss on disposal of property and equipment

—

0.9

—

0.4

Non-GAAP gross margin percentage

56.3

54.1

57.0

55.6

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

Continuing Operations

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Operating expenses

35,923

36,325

59,727

74,344

Restructuring and related charges

(2,812

)

(1,727

)

(5,892

)

(3,279

)

Transaction and integration expenses

(14,747

)

(271

)

(14,747

)

(1,474

)

Stock-based compensation expense

(3,597

)

(4,970

)

(8,057

)

(12,777

)

Depreciation and amortization

(941

)

(1,451

)

(1,957

)

(3,277

)

Gain on disposal of property and equipment

—

Non-GAAP operating expenses

13,832

27,906

29,114

53,537

R&D operating expenses

1,976

6,222

4,093

11,662

Stock-based compensation expense

(189

)

(481

)

(351

)

(820

)

Depreciation and amortization

(157

)

(630

)

(325

)

(769

)

Gain on disposal of property and equipment

—

Non-GAAP R&D operating expenses

1,630

5,167

3,417

10,101

SG&A operating expenses

16,388

28,105

34,995

57,929

Stock-based compensation expense

(3,408

)

(4,489

)

(7,706

)

(11,957

)

Depreciation and amortization

(784

)

(821

)

(1,632

)

(2,508

)

Gain on disposal of property and equipment

(56

)

(28

)

Non-GAAP SG&A operating expenses

12,202

22,739

25,697

43,436

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

Continuing Operations

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Net loss from continuing operations

(21,525

)

(17,673

)

(36,151

)

(41,043

)

Income tax (benefit) expense

(609

)

101

(728

)

Interest income, net

(4,611

)

(2,452

)

(8,122

)

(5,366

)

Depreciation and amortization

1,279

2,005

2,641

4,094

Restructuring and related charges

2,812

1,727

5,892

3,279

Transaction and integration expenses

14,747

271

14,747

1,474

Stock-based compensation expense

4,050

5,372

9,051

13,421

(Gain) loss on disposal of property and equipment

)

187

(40

)

187

Other non-operating (income) expense

658

(4,963

)

6,288

(5,530

)

Adjusted EBITDA

(2,506

)

(16,135

)

(5,593

)

(30,212

)

GRAPHIC

Filename: img96762296_0.gif · Sequence: 3

Binary file (30377 bytes)

Download img96762296_0.gif

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document and Entity Information

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity File Number

001-34180

Entity Registrant Name

Standard BioTools Inc.

Entity Central Index Key

0001162194

Entity Tax Identification Number

77-0513190

Entity Incorporation, State or Country Code

Entity Address, Address Line One

50 Milk Street

Entity Address, Address Line Two

10th Floor

Entity Address, City or Town

Boston

Entity Address, State or Province

Entity Address, Postal Zip Code

02109

City Area Code

650

Local Phone Number

266-6000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value per share

Trading Symbol

LAB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration